SCHEMBL3852096

SCHEMBL3852096

CC(I)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19703051 0.90
SCHEMBL27108245 0.90
SCHEMBL19241756 0.90
SCHEMBL8395064 0.86
SCHEMBL22185231 0.86
SCHEMBL8271701 0.86
SCHEMBL23551103 0.85
SCHEMBL1842412 0.83
SCHEMBL12948970 0.83
SCHEMBL24324448 0.81 CYP2D6 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017189661-A1 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT JANSSEN PHARMACEUTICA NV (BE) 2017-11-02 WO disclosed
EP-2678315-B1 (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR JANSSEN PHARMACEUTICA NV (BE) 2015-12-16 EP disclosed
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-8985173-B2 Manufacturing method and manufacturing apparatus of semiconductor substrate SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-03-24 US disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
WO-2013112751-A1 POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-08-01 WO disclosed
US-20130177530-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-07-11 US disclosed
WO-2012125661-A1 SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-09-20 WO disclosed
CN-102161673-A Belta-halo ring propyl silane derivative XIANGGUO LIU 2011-08-24 CN disclosed
US-20100300862-A1 Touch Panel SEMICONDUCTOR ENERGY LABORATORIES, CO., LTD. 2010-12-02 US disclosed
US-20040023955-A1 Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors RODGERS JAMES D (US) 2004-02-05 US disclosed
US-6596729-B2 Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 BRISTOL-MYERS SQUIBB COMPANY 2003-07-22 US disclosed
EP-1303515-A2 TRICYCLIC 2-PYRIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2003-04-23 EP disclosed
US-20020107261-A1 Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors DUPONT PHARMACEUTICALS COMPANY 2002-08-08 US disclosed
WO-2002008226-A2 TRICYCLIC 2-PYRIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-31 WO disclosed
CN-1017900-B PROCESS FOR PRODUCTION OF ELLIPTICINE DERIVATIVE SUNTORY LTD (JP) 1992-08-19 CN disclosed
EP-0173462-B1 ELLIPTICINE DERIVATIVE AND PRODUCTION PROCESS THEREOF SUNTORY LIMITED (JP) 1989-10-25 EP disclosed
US-4698423-A ANTITUMOR AGENTS SUNTORY LIMITED (JP) 1987-10-06 US disclosed
CN-85107911-A The production method of ellipticine derivative 1987-02-25 CN disclosed
EP-0173462-A2 Ellipticine derivative and production process thereof SUNTORY LIMITED (JP) 1986-03-05 EP disclosed